Fate Therapeutics. has been granted a patent for compositions and methods that enhance immune cell populations, specifically T, NK, and NKT cells, through the use of a PDK1 inhibitor. This approach aims to improve therapeutic outcomes in adoptive cell therapies by selectively modulating lymphocyte signaling. GlobalData’s report on Fate Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Fate Therapeutics, T-cell culturing was a key innovation area identified from patents. Fate Therapeutics's grant share as of June 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Immune cell modulation for enhanced adoptive cell therapies
The granted patent US12036241B2 outlines a novel composition that combines a population of lymphocytes with a Phosphoinositide-dependent kinase-1 (PDK1) inhibitor. This composition is designed to enhance the therapeutic potential of specific subpopulations of lymphocytes by selectively inhibiting AKT-independent signaling pathways. The claims detail various benefits of this approach, including improved cell expansion, differentiation, survival rates, and overall therapeutic efficacy. The lymphocytes can be derived from various sources, including peripheral blood, bone marrow, and tumors, and may include T cells, NKT cells, and NK cells. The patent also specifies that the lymphocytes can be genetically modified to enhance their functionality, incorporating elements such as T Cell Receptors (TCRs) or Chimeric Antigen Receptors (CARs).
Additionally, the patent describes methods for modulating lymphocytes using the PDK1 inhibitor, which can lead to improved proliferation, cytotoxicity, and cytokine responses. The claims emphasize the potential for these modulated lymphocytes to be utilized in adoptive cell therapies, providing a framework for developing advanced immunotherapies. The PDK1 inhibitor mentioned, GSK2334470, is highlighted as a key component of the composition. Furthermore, the patent allows for the inclusion of various additives and organic solvents to enhance the therapeutic composition, indicating a comprehensive approach to optimizing lymphocyte-based treatments for various medical conditions, including autoimmune diseases and cancers.
To know more about GlobalData’s detailed insights on Fate Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
